In addition, a novel activation loop mutation, G846S (exon 20), was identified in patient 22. Patients were also genotyped for mutations in KIT, another SU11248 target….These data clearly demonstrate that a single dose of SU11248 results in inhibition of FLT3 phosphorylation in a dose-dependent manner in AML patients, with inhibition in all genotypes.